CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Total Stockholders' Equity	Total Stockholders' Equity Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Capital In Excess of Par Value	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2019					198,630
Beginning balance at Dec. 31, 2019	$ 12,037	$ (2)	$ 12,037	$ (2)	$ 33	$ 2,820	$ 17,483	$ (2)	$ 156	$ (8,455)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,367		3,367				3,367
Other comprehensive loss	235		235						235
Common stock repurchases	(1,820)		(1,820)			(263)				(1,557)
Dividends and dividend equivalents	(331)		(331)				(331)
Stock-based compensation	181		181			181
Restricted stock unit vesting (in shares)					19
Restricted stock unit vesting	0					(59)				59
Stock option exercises	61		61			26				35
Ending balance (in shares) at Dec. 31, 2020					198,649
Ending balance at Dec. 31, 2020	13,728		13,728		$ 33	2,705	20,517		391	(9,918)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,934		2,933				2,933				1
Acquisition	22										22
Other comprehensive loss	(349)		(349)						(349)
Common stock repurchases	(79)		(79)			262				(341)
Dividends and dividend equivalents	(364)		(364)				(364)
Stock-based compensation	180		180			180
Restricted stock unit vesting	0		0			(81)				81
Stock option exercises	31		31			16				15
Ending balance (in shares) at Dec. 31, 2021					198,649
Ending balance at Dec. 31, 2021	16,103		16,080		$ 33	3,082	23,086		42	(10,163)	23
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,802		2,806				2,806				(4)
Distribution to noncontrolling interest holders, net	(1)										(1)
Sale of KAH Hospice	(11)										(11)
Acquisition	52										52
Other comprehensive loss	(1,346)		(1,346)						(1,346)
Common stock repurchases	(2,096)		(2,096)							(2,096)
Dividends and dividend equivalents	(400)		(400)				(400)
Stock-based compensation	216		216			216
Restricted stock unit vesting (in shares)					18
Restricted stock unit vesting	0					(78)				78
Stock option exercises	51		51			26				25
Ending balance (in shares) at Dec. 31, 2022					198,667
Ending balance at Dec. 31, 2022	$ 15,370		$ 15,311		$ 33	$ 3,246	$ 25,492		$ (1,304)	$ (12,156)	$ 59